U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C26H27N3O5S
Molecular Weight 493.575
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DASABUVIR

SMILES

COC1=C(C=C(C=C1C(C)(C)C)N2C=CC(=O)NC2=O)C3=CC4=CC=C(NS(C)(=O)=O)C=C4C=C3

InChI

InChIKey=NBRBXGKOEOGLOI-UHFFFAOYSA-N
InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)

HIDE SMILES / InChI

Molecular Formula C26H27N3O5S
Molecular Weight 493.575
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/26567871

Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B palm polymerase inhibitor. It is used in the treatment of adult patients with chronic hepatitis C virus infection in combination with ombitasvir, paritaprevir, and ritonavir as the combination product Viekira Pak. Viekira PAK combines three direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle. Dasabuvir is extensively evaluated in large clinical trials and shown excellent sustained virological response among hepatitis C virus genotype1 patient population in combination with other oral direct acting antivirals, with good safety profile and tolerance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.8 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIEKIRA PAK (COPACKAGED)

Approved Use

Treatment of adult patients with chronic hepatitis C virus (HCV): genotype 1b without cirrhosis or with compensated cirrhosis, genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
320 ng/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
912 ng/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1130 ng/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2110 ng/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2620 ng × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7050 ng × h/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8800 ng × h/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15800 ng × h/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.87 h
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.87 h
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.52 h
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.1%
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.1%
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.1%
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DASABUVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1600 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 2 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
2000 mg single, oral
Highest studied dose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
PubMed

PubMed

TitleDatePubMed
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection.
2014
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
2015 Mar
Patents

Sample Use Guides

250 mg tablet twice daily (morning and evening) with a meal without regard to fat or calorie content.
Route of Administration: Oral
The EC50 values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively. The median EC50 values of dasabuvir against HCV replicons containing NS5B genes from a panel of genotype 1a and 1b isolates from treatment-naïve subjects were 0.6 nM (range 0.4 nM to 2.1 nM; n = 11) and 0.3 nM (range 0.2 nM to 2 nM; n = 10), respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:39:37 GMT 2025
Edited
by admin
on Mon Mar 31 18:39:37 GMT 2025
Record UNII
DE54EQW8T1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ABT-333
Preferred Name English
DASABUVIR
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
dasabuvir [INN]
Common Name English
N-(6-(3-TERT-BUTYL-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)-2-METHOXYPHENYL)NAPHTHALEN-2-YL)METHANESULFONAMIDE
Systematic Name English
DASABUVIR [MI]
Common Name English
METHANESULFONAMIDE, N-(6-(5-(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)-3-(1,1-DIMETHYLETHYL)-2-METHOXYPHENYL)-2-NAPHTHALENYL)-
Systematic Name English
DASABUVIR [USAN]
Common Name English
Dasabuvir [WHO-DD]
Common Name English
DASABUVIR [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AX66
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
WHO-ATC J05AP09
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
WHO-ATC J05AP52
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
FDA ORPHAN DRUG 484715
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
NCI_THESAURUS C281
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
NDF-RT N0000191257
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
WHO-ATC J05AX16
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
Code System Code Type Description
LACTMED
Dasabuvir
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
SMS_ID
100000156931
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
CAS
1132935-63-7
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
EVMPD
SUB131059
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
USAN
BC-08
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
FDA UNII
DE54EQW8T1
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
PUBCHEM
56640146
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
RXCUI
1597381
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB09183
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
WIKIPEDIA
Dasabuvir
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
MERCK INDEX
m11828
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
ChEMBL
CHEMBL3137312
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
CAS
1221573-79-0
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
NO STRUCTURE GIVEN
CHEBI
85182
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID301025953
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
NDF-RT
N0000191272
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY UGT1A1 Inhibitors [MoA]
INN
9741
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
NDF-RT
N0000190113
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
DRUG CENTRAL
4914
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
NDF-RT
N0000191258
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY RNA Replicase Inhibitors [MoA]
NCI_THESAURUS
C123880
Created by admin on Mon Mar 31 18:39:37 GMT 2025 , Edited by admin on Mon Mar 31 18:39:37 GMT 2025
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
TARGET ORGANISM->INHIBITOR
strain Con1
IC50
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
IC50
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
FECAL
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA; URINE
METABOLITE -> PARENT
PLASMA; URINE
METABOLITE -> PARENT
PLASMA; URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
blood-to-plasma ratio PHARMACOKINETIC